Amanda Sheppeard

Amanda Sheppeard is a managing editor and health journalist who connects complex clinical developments and disability policy with the day-to-day realities of doctors and patients across The Medical Republic and its specialist titles. Her work stands out for long, detailed explainer pieces that track how emerging research, therapies and political narratives reshape care, especially around autism, autoimmune disease and infectious threats. She works across editorial leadership and commercial content while continuing to report widely on medicine, giving her coverage a system-level view that many single-beat reporters do not have.

Autism, disability policy and the impact of public narratives

Autism and disability policy are a recurring thread in Sheppeard’s reporting, where she treats neurodevelopment and the National Disability Insurance Scheme as intertwined clinical and political subjects rather than separate beats. In a comment piece on early autism diagnosis, she argues that access to disability support should be based on individual needs rather than diagnostic levels, highlighting planned reforms to move the NDIS away from a deficits-based model. She traces how early intervention changes outcomes for autistic children and families, and frames policy changes in terms of what they mean in clinic rooms and assessment services rather than only in legislative language.

Her coverage of Trump’s public claims about autism and vaccines extends this focus into media and search behaviour, documenting how high-profile political statements can drive online searches and anxiety among parents and carers. Taken together, these autism pieces show a reporter who treats neurodiversity as both a clinical subject and a social system, unpicking how funding rules, public rhetoric and diagnostic practice feed back into each other in real time.

Translating complex clinical research for specialist audiences

Across The Medical Republic’s sister mastheads, Sheppeard writes detailed explainers on specialty medicine that synthesise genetics, trial data and therapeutic strategy for clinicians. Her Rheumatology Republic feature on “rheumatology’s biggest clinical shifts of 2025” tracks how fibromyalgia genetics, TYK2 inhibitor breakthroughs and in vivo CAR T-cell therapy are pushing the field from pathway-based protocols toward mechanism-first care, explaining why these developments alter what patients are offered and when. She breaks down the science behind emerging treatments such as oral zasocitinib for psoriatic arthritis, linking its TYK2 selectivity to joint and skin outcomes, and sets these against familiar JAK-pathway approaches so specialists can see the practical distinctions.

Sheppeard’s coverage of weight-loss agents like semaglutide and tirzepatide in rheumatoid arthritis similarly balances enthusiasm with caution, noting evidence that they may reduce disease activity and pain while improving metabolic risk profiles. In the same piece, she reports on Novartis’ secukinumab trial in giant cell arteritis, explaining how failure to meet the primary endpoint on sustained remission at 52 weeks shapes the prospects for biologic therapy in that condition. This pattern of walking readers through both positive signals and unmet endpoints recurs elsewhere: in Dermatology Republic she covers microneedle technology as a “three-pronged attack on psoriasis”, and contrasts stem cell and gene therapy approaches in sickle cell disease, emphasising mechanisms, delivery platforms and real-world limitations.

Her work on delusional infestation care shows a willingness to tackle conditions at the intersection of dermatology and psychiatry, reporting on attempts to reach consensus on management while acknowledging the gaps that remain. Across these pieces, Sheppeard distinguishes herself by doing the synthesis work inside the story — connecting trial design, molecular targets and funding landscapes — rather than simply relaying headline results.

Primary care, hospitals and system pressures

At The Medical Republic, Sheppeard regularly reports on pressures in primary care and hospital practice, treating them as part of a single health system rather than isolated settings. In a piece on asthma control, she links sliding control rates to the rise of urgent care services, showing how changing access points for care can alter chronic disease management and follow-up. Her reporting on “phones in hospitals crawling with superbugs” uses infection-control research to highlight everyday risks on wards, translating microbiology findings into practical questions about cleaning protocols and device policies.

She has covered the “PBS future of two leading MS therapies”, examining how reimbursement decisions affect neurologists’ prescribing options and long-term patient access to disease-modifying treatments. Earlier work on a “huge rise in Aussies on kidney replacement therapy” brings together epidemiology and service planning, drawing attention to the growing burden of renal disease and the infrastructure required to support dialysis and transplantation. A piece titled “Double agents fight bacteria” reflects her interest in antimicrobial resistance and innovative approaches to infectious disease, a theme that has seen her reporting recognised with a regional media award for coverage of AMR issues.

In coverage flagged on The Medical Republic’s social channels as a “shake-up for the doctor’s bag”, Sheppeard reports that high prices and falling risk profiles are driving general practitioners to rely more on pharmacies than on their own bags, capturing subtle shifts in prescribing and supply that alter everyday GP practice. Across these system-focused stories, she consistently links clinical findings to workflow, funding and safety implications, helping readers understand not just what is happening but how it will change their working environment.

Editorial leadership and cross-title reach

Sheppeard holds a managing editor and commercial content manager role at The Medical Republic, combining newsroom leadership with hands-on reporting. Her byline spans Dermatology Republic, Rheumatology Republic and Oncology Republic, indicating a broad remit across specialties that range from dermatology and rheumatology to medical oncology, nephrology, neurology and neonatal medicine. That spread allows her to follow themes — such as autoimmune disease, infection control and new modalities like CAR T-cell therapy or microneedles — across different disciplines and patient groups.

Her dual editorial and reporting responsibilities mean she writes with an awareness of audience needs and commercial realities, tailoring pieces that are both clinically rich and accessible to busy practitioners. Whether she is unpacking AI’s “co-intelligence” role in reshaping medical research, covering a historic $100m package for arthritis research or analysing policy shifts around autism and the NDIS, Sheppeard’s work maintains a consistent focus on how macro-level changes translate into concrete decisions in clinics and hospitals. That combination of cross-specialty reach, technical synthesis and policy literacy defines her coverage and sets it apart from more narrowly focused health news reporting.